Capital Square’s Neurocrine Biosciences NBIX Stock Holding History

Capital Square’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$225K	Buy	+1,270	New	+$188K	0.1%	208

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Square's NBIX Position: Q2 2026 in Review

Capital Square opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,270 shares worth $225K. The stake represents 0.1% of the portfolio and ranks #208 among its holdings.

772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Capital Square held 1,270 shares of Neurocrine Biosciences worth $225K as of Q2 2026.
Neurocrine Biosciences was a new Capital Square position in Q2 2026.
Neurocrine Biosciences made up 0.1% of Capital Square's portfolio in Q2 2026, its #208 holding.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Capital Square's 13F filing for Q2 2026, filed 13 Aug 2026.